Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GW-1000. GW Pharmaceuticals.

Paul F Smith1

  • 1University of Otago, Department of Pharmacology and Toxicology, School of Medical Sciences, Dunedin, New Zealand. paul.smith@stonebow.otago.ac.nz

Current Opinion in Investigational Drugs (London, England : 2000)
|August 10, 2004
PubMed
Summary

GW Pharmaceuticals is developing GW-1000 (Sativex), a cannabinoid product, for multiple sclerosis and other neurological conditions. Regulatory submissions were made in the UK and Canada for its potential therapeutic use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zn<sub>3-<i>x</i></sub>H<sub>2<i>x</i></sub>(OH)<sub>2</sub>(MoO<sub>4</sub>)<sub>2</sub>·H<sub>2</sub>O: a crystallographically accurate Φ<sub><i>y</i></sub>-type structure of "Zn<sub>5</sub>Mo<sub>2</sub>O<sub>11</sub>·5H<sub>2</sub>O".

Chemical communications (Cambridge, England)·2026
Same author

Deep brain reconditioning stimulation suppresses tinnitus in a rat model.

Scientific reports·2026
Same author

The impact of balance exercise on brain age and brain morphometry: insights from MRI analysis.

Aging clinical and experimental research·2026
Same author

Optimizing noisy galvanic vestibular stimulation (nGVS) for postural control: methodological considerations when individualizing the signal for people with bilateral vestibulopathy.

Frontiers in neurology·2025
Same author

Hearing and balance research in Aotearoa New Zealand: sound and stable foundations for the future.

Journal of the Royal Society of New Zealand·2025
Same author

A scoping review of tinnitus research undertaken by New Zealand researchers: Aotearoa-an international hotspot for tinnitus innovation and collaboration.

Journal of the Royal Society of New Zealand·2025

Area of Science:

  • Neurology
  • Pharmacology
  • Drug Development

Background:

  • GW Pharmaceuticals is developing GW-1000, also known as Sativex.
  • This product is a specific ratio of delta9-tetrahydrocannabinol and cannabidiol.

Purpose of the Study:

  • To evaluate GW-1000 (Sativex) as a potential treatment.
  • Investigate its efficacy for multiple sclerosis, spinal cord injury, neurogenic pain, and peripheral neuropathy.

Main Methods:

  • Regulatory filings submitted to health authorities.
  • Specifically, a submission to the UK Medicines Control Agency in March 2003 for multiple sclerosis treatment.
  • A new drug submission to Health Canada in May 2004.

Main Results:

  • Regulatory applications have been filed for GW-1000 (Sativex).
  • The company is seeking approval for its use in treating neurological conditions.

Conclusions:

  • GW-1000 (Sativex) is under regulatory review for multiple sclerosis and other neurological disorders.
  • The development signifies a potential new therapeutic option for patients with these conditions.

Related Experiment Videos